{"id":14391,"date":"2021-08-10T09:20:24","date_gmt":"2021-08-10T07:20:24","guid":{"rendered":"https:\/\/ggba.swiss\/womens-health-biopharmaceutical-company-obseva-receives-usd-500-million\/"},"modified":"2023-07-04T13:40:20","modified_gmt":"2023-07-04T11:40:20","slug":"womens-health-biopharmaceutical-company-obseva-receives-usd-500-million","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/en\/womens-health-biopharmaceutical-company-obseva-receives-usd-500-million\/","title":{"rendered":"Women\u2019s health biopharmaceutical company ObsEva receives USD 500 million"},"content":{"rendered":"

ObsEva<\/a> is a biopharmaceutical company developing and commercializing novel therapies to improve women\u2019s reproductive health and pregnancy.<\/p>\n

Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on new therapies for the treatment of uterine fibroids, endometriosis, and preterm labor.<\/p>\n

The company candidate, ebopiprant<\/a>, is an investigational, orally active, selective prostaglandin receptor antagonist being evaluated as a potential treatment for preterm labor by reducing inflammation and uterine contractions.<\/p>\n

If approved, ebopiprant has the potential to become a first-in-class innovation for this common and serious condition with no approved therapies for acute treatment of preterm labour in the United States.<\/p>\n

By entering into an agreement with Organon<\/a>, a global women\u2019s health company, ObsEva will license the global development, manufacturing and commercial rights of ebopiprant. The Geneva-based company will receive up to USD 500 million, USD 25 million of which in upfront payment.<\/p>\n

Organon intends to work with the scientific and medical communities and regulatory authorities in major markets, including the United States, to advance the clinical development and registration of ebopiprant.<\/p>\n

Brian O\u2019Callaghan, CEO of ObsEva, commented: “Organon is the ideal partner for the development and commercialization of ebopiprant and we see this agreement as an important step in advancing this investigational agent. Although preterm birth rates are on the rise, there are currently no other known compounds in development. That is why we are focused on evaluating this agent in an important area of unmet need. Together with the data generated to date, this agreement underscores the value of our program, and we look forward to executing on our shared vision.”<\/p>\n","protected":false},"excerpt":{"rendered":"

ObsEva, a Geneva-based biopharmaceutical company dedicated to improving women\u2019s reproductive health, will receive up to USD 500 million for the licensing of its candidate ebopiprant.<\/p>\n","protected":false},"author":3,"featured_media":14392,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[833],"tags":[912,902,911],"class_list":["post-14391","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-life-science","tag-biotech","tag-personalized-medicine","tag-pharma"],"acf":[],"yoast_head":"\nWomen\u2019s health biopharmaceutical company ObsEva receives USD 500 million - Greater Geneva Bern area<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/staging.ggba.swiss\/en\/womens-health-biopharmaceutical-company-obseva-receives-usd-500-million\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Women\u2019s health biopharmaceutical company ObsEva receives USD 500 million - Greater Geneva Bern area\" \/>\n<meta property=\"og:description\" content=\"ObsEva, a Geneva-based biopharmaceutical company dedicated to improving women\u2019s reproductive health, will receive up to USD 500 million for the licensing of its candidate ebopiprant.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/staging.ggba.swiss\/en\/womens-health-biopharmaceutical-company-obseva-receives-usd-500-million\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2021-08-10T07:20:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-07-04T11:40:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/staging.ggba.swiss\/app\/uploads\/2023\/06\/ObsEva-630x380-4.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"630\" \/>\n\t<meta property=\"og:image:height\" content=\"380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"mathieu\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"mathieu\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/womens-health-biopharmaceutical-company-obseva-receives-usd-500-million\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/womens-health-biopharmaceutical-company-obseva-receives-usd-500-million\/\"},\"author\":{\"name\":\"mathieu\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab\"},\"headline\":\"Women\u2019s health biopharmaceutical company ObsEva receives USD 500 million\",\"datePublished\":\"2021-08-10T07:20:24+00:00\",\"dateModified\":\"2023-07-04T11:40:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/womens-health-biopharmaceutical-company-obseva-receives-usd-500-million\/\"},\"wordCount\":279,\"image\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/womens-health-biopharmaceutical-company-obseva-receives-usd-500-million\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/ObsEva-630x380-4.jpg\",\"keywords\":[\"Biotech\",\"Personalized Medicine\",\"Pharma\"],\"articleSection\":[\"Life sciences\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/womens-health-biopharmaceutical-company-obseva-receives-usd-500-million\/\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/womens-health-biopharmaceutical-company-obseva-receives-usd-500-million\/\",\"name\":\"Women\u2019s health biopharmaceutical company ObsEva receives USD 500 million - Greater Geneva Bern area\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/womens-health-biopharmaceutical-company-obseva-receives-usd-500-million\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/womens-health-biopharmaceutical-company-obseva-receives-usd-500-million\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/ObsEva-630x380-4.jpg\",\"datePublished\":\"2021-08-10T07:20:24+00:00\",\"dateModified\":\"2023-07-04T11:40:20+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab\"},\"breadcrumb\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/womens-health-biopharmaceutical-company-obseva-receives-usd-500-million\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/staging.ggba.swiss\/en\/womens-health-biopharmaceutical-company-obseva-receives-usd-500-million\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/womens-health-biopharmaceutical-company-obseva-receives-usd-500-million\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/ObsEva-630x380-4.jpg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/ObsEva-630x380-4.jpg\",\"width\":630,\"height\":380},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/womens-health-biopharmaceutical-company-obseva-receives-usd-500-million\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Women\u2019s health biopharmaceutical company ObsEva receives USD 500 million\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab\",\"name\":\"mathieu\",\"url\":\"https:\/\/ggba.swiss\/en\/author\/mathieu\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Women\u2019s health biopharmaceutical company ObsEva receives USD 500 million - Greater Geneva Bern area","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/staging.ggba.swiss\/en\/womens-health-biopharmaceutical-company-obseva-receives-usd-500-million\/","og_locale":"en_US","og_type":"article","og_title":"Women\u2019s health biopharmaceutical company ObsEva receives USD 500 million - Greater Geneva Bern area","og_description":"ObsEva, a Geneva-based biopharmaceutical company dedicated to improving women\u2019s reproductive health, will receive up to USD 500 million for the licensing of its candidate ebopiprant.","og_url":"https:\/\/staging.ggba.swiss\/en\/womens-health-biopharmaceutical-company-obseva-receives-usd-500-million\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2021-08-10T07:20:24+00:00","article_modified_time":"2023-07-04T11:40:20+00:00","og_image":[{"width":630,"height":380,"url":"https:\/\/staging.ggba.swiss\/app\/uploads\/2023\/06\/ObsEva-630x380-4.jpg","type":"image\/jpeg"}],"author":"mathieu","twitter_card":"summary_large_image","twitter_misc":{"Written by":"mathieu","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/staging.ggba.swiss\/en\/womens-health-biopharmaceutical-company-obseva-receives-usd-500-million\/#article","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/womens-health-biopharmaceutical-company-obseva-receives-usd-500-million\/"},"author":{"name":"mathieu","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab"},"headline":"Women\u2019s health biopharmaceutical company ObsEva receives USD 500 million","datePublished":"2021-08-10T07:20:24+00:00","dateModified":"2023-07-04T11:40:20+00:00","mainEntityOfPage":{"@id":"https:\/\/staging.ggba.swiss\/en\/womens-health-biopharmaceutical-company-obseva-receives-usd-500-million\/"},"wordCount":279,"image":{"@id":"https:\/\/staging.ggba.swiss\/en\/womens-health-biopharmaceutical-company-obseva-receives-usd-500-million\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/ObsEva-630x380-4.jpg","keywords":["Biotech","Personalized Medicine","Pharma"],"articleSection":["Life sciences"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/staging.ggba.swiss\/en\/womens-health-biopharmaceutical-company-obseva-receives-usd-500-million\/","url":"https:\/\/staging.ggba.swiss\/en\/womens-health-biopharmaceutical-company-obseva-receives-usd-500-million\/","name":"Women\u2019s health biopharmaceutical company ObsEva receives USD 500 million - Greater Geneva Bern area","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/staging.ggba.swiss\/en\/womens-health-biopharmaceutical-company-obseva-receives-usd-500-million\/#primaryimage"},"image":{"@id":"https:\/\/staging.ggba.swiss\/en\/womens-health-biopharmaceutical-company-obseva-receives-usd-500-million\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/ObsEva-630x380-4.jpg","datePublished":"2021-08-10T07:20:24+00:00","dateModified":"2023-07-04T11:40:20+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab"},"breadcrumb":{"@id":"https:\/\/staging.ggba.swiss\/en\/womens-health-biopharmaceutical-company-obseva-receives-usd-500-million\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/staging.ggba.swiss\/en\/womens-health-biopharmaceutical-company-obseva-receives-usd-500-million\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/staging.ggba.swiss\/en\/womens-health-biopharmaceutical-company-obseva-receives-usd-500-million\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/ObsEva-630x380-4.jpg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/ObsEva-630x380-4.jpg","width":630,"height":380},{"@type":"BreadcrumbList","@id":"https:\/\/staging.ggba.swiss\/en\/womens-health-biopharmaceutical-company-obseva-receives-usd-500-million\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/en\/"},{"@type":"ListItem","position":2,"name":"Women\u2019s health biopharmaceutical company ObsEva receives USD 500 million"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab","name":"mathieu","url":"https:\/\/ggba.swiss\/en\/author\/mathieu\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/14391","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/comments?post=14391"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/14391\/revisions"}],"predecessor-version":[{"id":16973,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/14391\/revisions\/16973"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media\/14392"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media?parent=14391"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/categories?post=14391"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/tags?post=14391"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}